C. Scart-Grès

发表

Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy

J. Schwartz, B. Setnik, P. Robert, 2019, Sleep.

Full manuscript with supplementary data

Laura Bossi, Philippe Lehert, Serguei Nabirotchkin, 2015 .

Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial

J. Pépin, J. Schwartz, M. Partinen, 2020, American Journal of Respiratory and Critical Care Medicine.

[Review of cases of prolonged QTC and wave burst arrhythmia in patients treated with methadone].

S. Richa, X. Laqueille, M. Berleur, 2012, L'Encephale.

[Recommendations for the creation of neuro-vascular units].

M. Hommel, J. Perret, D. Leys, 2001, Revue neurologique.

Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study

J. Pépin, H. Bastuji, I. Arnulf, 2019, Sleep.

Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial

J. Pépin, J. Schwartz, M. Partinen, 2020, American journal of respiratory and critical care medicine.

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

I. Chumakov, J. Pouget, Serguei Nabirotchkin, 2014, Orphanet Journal of Rare Diseases.

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy

I. Chumakov, Esther Graudens, Serguei Nabirotchkin, 2015, Scientific Reports.

A proof‐of‐concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease

J. Kulisevsky, N. Reig, M. Calopa, 2022, British Journal of Clinical Pharmacology.

Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

I. Chumakov, J. Pouget, Serguei Nabirotchkin, 2016, Orphanet Journal of Rare Diseases.

A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment

I. Chumakov, Daniel Cohen, J. Micallef, 2015, Orphanet Journal of Rare Diseases.